GSK R&D , King of Prussia, Pennsylvania , USA.
GSK R&D , Research Triangle Park, North Carolina , USA.
BMJ Open Respir Res. 2016 Sep 8;3(1):e000151. doi: 10.1136/bmjresp-2016-000151. eCollection 2016.
Sputum and blood eosinophil counts have attracted attention as potential biomarkers in chronic obstructive pulmonary disease (COPD). One question regarding the use of blood eosinophils as a biomarker in COPD is whether their levels are affected by the use of inhaled corticosteroids (ICS), which are commonly prescribed for COPD.
We performed a retrospective analysis of peripheral blood leucocytes from a previously completed clinical trial that examined effects of ICS in steroid-naïve patients with COPD.
The data show that the ICS-containing treatment arms (containing fluticasone propionate) had a small effect on peripheral blood eosinophils in steroid-naïve patients with COPD.
NCT00358358; Post-results.
痰和血嗜酸性粒细胞计数作为慢性阻塞性肺疾病（COPD）的潜在生物标志物引起了关注。关于血液嗜酸性粒细胞作为 COPD 生物标志物的使用有一个问题，即它们的水平是否受到吸入性皮质类固醇（ICS）的影响，ICS 常用于治疗 COPD。
我们对以前完成的一项临床试验中的外周血白细胞进行了回顾性分析，该试验检查了 ICS 在 COPD 初治患者中的作用。
数据表明，ICS 治疗组（含有丙酸氟替卡松）对 COPD 初治患者的外周血嗜酸性粒细胞有轻微影响。
NCT00358358；试验后。
